New launches to help Biocon Biologics reach $1 bn revenue target by FY22: Christiane Hamacher
The biologics segment grew 50 percent year-on-year (YoY) in nine-month period to Rs 1594 crores, led primarily by contributions from Pegfilgrastim and Trastuzumab in US market.